Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. has received approval from the Stock Exchange of Hong Kong for the listing and trading of 182,645,856 converted H shares, enabling full circulation of these previously unlisted shares. The conversion involves 17 participating shareholders whose newly listed holdings represent about 33.61% of the company’s total issued share capital, a move that is expected to enhance liquidity in Henlius’s stock, broaden its investor base and potentially improve capital-market access for both the company and its strategic shareholders.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-incorporated biopharmaceutical company listed in Hong Kong, operating in the biotechnology and life sciences sector with a focus on developing and commercialising biologic drugs. Its capital structure includes H shares listed on the Stock Exchange of Hong Kong and previously unlisted shares held by various institutional and strategic investors.
Average Trading Volume: 968,167
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.09B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.